Von Hippel-Lindau (VHL) disease is an autosomal dominant inherited familial cancer syndrome characterised by a predisposition to the development of retinal, cerebellar, and spinal haemangioblastomas, renal cell carcinoma, and phaeochromocytoma. The gene for VHL disease has been mapped to chromosome 3p25-p26 and flanking markers identified. We report the detailed genetic mapping of the VHL disease locus in 38 families. Significant linkage was detected between VHL disease and D3S601 (Zmax= 18-86 at 0= 0 0, CI 0-0-0 025), D3S18 (Zmax = 11P42 at 0 = 0 03, CI 0-005-0-08), RAFI (Zmax= 11-02 at 0=0'04, CI 0-007-0-01), and D3S1250 (Zmax=4 73 at 0= 0 05, CI 0 005-0 15
Abstract
Von Hippel-Lindau (VHL) disease is an autosomal dominant inherited familial cancer syndrome characterised by a predisposition to the development of retinal, cerebellar, and spinal haemangioblastomas, renal cell carcinoma, and phaeochromocytoma. The gene for VHL disease has been mapped to chromosome 3p25-p26 and flanking markers identified. We report the detailed genetic mapping of the VHL disease locus in 38 families. Significant linkage was detected between VHL disease and D3S601 (Zmax= 18-86 at 0= 0 0, CI 0-0-0 025), D3S18 (Zmax = 11P42 at 0 = 0 03, CI 0-005-0-08), RAFI (Zmax= 11-02 at 0=0'04, CI 0-007-0-01), and D3S1250 (Zmax=4 73 at 0= 0 05, CI 0 005-0 15). Multipoint linkage analysis mapped the VHL disease locus between D3S1250 and D3S18 close to D3S601. There was no evidence of locus heterogeneity. This study has (1) confirmed the tight linkage between VHL disease and D3S601, (2) identified D3S1250 as the first marker telomeric to RAFI which maps centromeric to the VHL disease gene, and (3) narrowed the target region for isolation of the VHL disease gene by positional cloning techniques to a 4 cM interval between D3S1250 and D3S18. These findings will improve the clinical management of families with VHL disease by improving the accuracy of presymptomatic diagnosis using linked DNA markers, and will enhance progress towards isolating the VHL disease gene. ( 26 times more Three affected subjects were recombinant at the RAFI locus. Two of these were also recombinant at D3S1250, placing the VHL disease gene telomeric to D3S1250. The -n D3S225 third RAFI recombinant subject was not recombinant at D3S1250. All three RAFI recombinant subjects were informative and non-recombinant at D3S601. Two D3S18 recombinant subjects were not recombinant at D3S601 or more centromeric markers. Homogeneity testing with the HOMOG program provided no evidence for locus heterogeneity; the most likely proportion of linked families (alpha) was 1-0 (95% confidence interval 0-85-1-0). The maximum lod score in a multipoint analysis for the six famil- Map distance (cM) Figure 3 Multipoint genetic linkage analysis for six VHL disease families containing patients affected by phaeochromocytoma (broken line) and 32 families not containing a subject with phaeochromocytoma (unbroken line).
suppressor gene in human cancers, and (3) increase the accuracy and availability of presymptomatic diagnosis of VHL disease using linked DNA markers.
We 
